Delisting risk
INM · NASDAQ · Drug Manufacturers - Specialty & Generic

InMed Pharmaceuticals (INM)

Develops cannabinoid-receptor small molecules for neurological, eye, and dermatology diseases.

$1.40
Pre-market+0.03 (+2.56%)
At close$1.37(+3.41%)

Breakdown13F · 13D/G · Form 4

Strategic holders3 holders · as of Jul 17, 202657.31%1.90M shares
Otherremainder42.69%1.41M shares

3.31M company shares as of Sep 3, 2026 · holders as of their latest filing

Two share counts disagree (3.31M in the company's Sep 3, 2026 report, 1.81M elsewhere); stakes use the report.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesEvidence
Vivo Opportunity, LLCStrategic10 percent owner
24.68%818,076Form 4filed Jul 16, 2026
ADAR1 Capital Management, LLCStrategic10 percent owner
24.17%801,000Form 4filed Jul 17, 2026
Squadron Master Fund LPInstitution
9.81%325,00013Gfiled May 27, 2026
Sabby Management, LLCStrategic
8.45%280,13813Gfiled Jan 20, 2026
Empery Asset Management, LPInstitution
4.99% of class, as filed13G/Afiled Jan 20, 2021
Hudson Bay Capital Management LPInstitution
3.81% of class, as filed13G/Afiled Feb 4, 2022
Steven BoydInsider
9.99% of class, as filed13D/Gfiled Feb 14, 2023
Vivo Opportunity Fund Holdings, L.P.Institution
21.70% of class, as filed13Dfiled Jun 10, 2026
Eric A. Adams1Insiderdirector, officer: President & CEO
0.07%2,198Form 4filed Feb 21, 2024
Andrew Hull2Insiderdirector
0.06%1,913Form 4filed Feb 22, 2024
Shane Aaron Johnson3Insiderofficer: SVP, GM of BayMedica LLC
0.02%609Form 4filed Jan 6, 2022
Bruce Colwill4Insiderofficer: CFO
0.00%23Form 4filed Jan 24, 2022
William J. Garner5Insiderdirector
0.00%8Form 4filed Nov 12, 2020
Eric C. Hsu5Insiderofficer: Sr VP, Pre-Clinical Res/Dev
0.00%3Form 4filed Nov 12, 2020
Michael Woudenberg5Insiderofficer: VP, Chem/Manufacturing/Control
0.00%1Form 4filed Nov 12, 2020
Alexandra Diane Janet Mancini6Insiderother: Consultant
0.00%0Form 4filed Aug 2, 2024
  1. Last filed Feb 21, 2024; leaving the company requires no filing. Not in the bar.
  2. Last filed Feb 22, 2024; leaving the company requires no filing. Not in the bar.
  3. Last filed Jan 6, 2022; leaving the company requires no filing. Not in the bar.
  4. Last filed Jan 24, 2022; leaving the company requires no filing. Not in the bar.
  5. Last filed Nov 12, 2020; leaving the company requires no filing. Not in the bar.
  6. Last filed Aug 2, 2024; leaving the company requires no filing. Not in the bar.

13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
ADAR1 Capital Management, LLC24.10%800.0K13GJun 5, 2026
Vivo Opportunity Fund Holdings, L.P.incl. Vivo Opportunity Cayman, LLC, Vivo Opportunity, LLC +1 more21.70%718.4K13DJun 10, 2026
Sabby Management, LLC9.90%280.1K13GJan 20, 2026
Squadron Master Fund LP9.80%325.0K13GMay 27, 2026
AdvisorShares Trust8.77%13GNov 12, 2024

Insider tradesForm 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Jul 15, 2026
ADAR1 Capital Management, LLC10 percent owner
Purchase1,000$1.56801,000
Jul 14, 2026
Vivo Opportunity, LLC10 percent owner
Purchase · 2 lots5,375$1.55729,277
Jul 15, 2026
Vivo Opportunity, LLC10 percent owner
Purchase · 2 lots15,150$1.55743,038
Jul 16, 2026
Vivo Opportunity, LLC10 percent owner
Purchase · 2 lots21$1.55743,057
Jun 30, 2026
Vivo Opportunity, LLC10 percent owner
Purchase · 2 lots600$1.54718,989
Jul 1, 2026
Vivo Opportunity, LLC10 percent owner
Purchase · 2 lots4,344$1.55722,935
Jul 2, 2026
Vivo Opportunity, LLC10 percent owner
Purchase · 2 lots1,607$1.55724,395
May 20, 2026
Vivo Opportunity, LLC10 percent owner
Purchase · 2 lots56,210$1.56543,129
May 21, 2026
Vivo Opportunity, LLC10 percent owner
Purchase · 2 lots34,000$1.69574,011
May 29, 2026
Vivo Opportunity, LLC10 percent owner
Purchase · 2 lots17,796$1.57590,175

CongressHouse and Senate disclosures

Not reported.